Status:
COMPLETED
Pharmacokinetics of Ertapenem in Continuous Venovenous Hemodialysis
Lead Sponsor:
University of Michigan
Conditions:
Acute Kidney Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Critically ill patients in the intensive care unit often receive continuous hemodialysis to treat their kidney failure. Ertapenem is an antibiotic often used in these patients. Continuous dialysis may...
Detailed Description
Subjects receiving CVVHD will receive a one gram dose of ertapenem. Serial blood samples over 24 hours will be taken to assess the ertapenem blood concentrations over time. Spent dialysate and urine s...
Eligibility Criteria
Inclusion
- Hospitalized in ICU
- Receiving Continuous hemodialysis
- Prescribed ertapenem
- Informed consent granted
Exclusion
- \< 18 years of age
- Allergy to ertapenem or other carbapenem antibiotic
- Severe, life-threatening reaction to penicillin or cephalosporins
- Patients experiencing or with history of CNS disorders (eg: seizure, stroke)
- Patients experiencing CNS infection
- Inability to complete 24 hours of CVVHD
- Concurrent use of other extracorporeal therapies such as extracorporeal membrane oxygenation, plasmapheresis or intermittent hemodialysis
- Inability to obtain informed consent
- Pregnant and/or breastfeeding women
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00877370
Start Date
February 1 2009
End Date
March 1 2011
Last Update
September 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan University Hospital
Ann Arbor, Michigan, United States, 48109